{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:39:51Z","timestamp":1793353191645,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,26]],"date-time":"2027-05-26T00:00:00Z","timestamp":1811289600000},"content-version":"am","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1 TR004399"],"award-info":[{"award-number":["UM1 TR004399"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["PROMISE-OB-18"],"award-info":[{"award-number":["PROMISE-OB-18"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2025.11.016","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T12:16:16Z","timestamp":1764418576000},"page":"450-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Elexacaftor\/tezacaftor\/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-4465","authenticated-orcid":false,"given":"Scott D.","family":"Sagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-0329","authenticated-orcid":false,"given":"Phuong","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya L.","family":"Heltshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1724-9868","authenticated-orcid":false,"given":"Andrea","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-1241","authenticated-orcid":false,"given":"Jessica","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-614X","authenticated-orcid":false,"given":"Margaret","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jcf.2025.11.016_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"issue":"10408","key":"10.1016\/j.jcf.2025.11.016_bib0002","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.016_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.016_bib0004","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1513\/AnnalsATS.201408-393OC","article-title":"A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis","volume":"12","author":"Habib","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.jcf.2025.11.016_bib0005","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.016_bib0006","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.016_bib0007","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2025.11.016_bib0008","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/ppul.26502","article-title":"Airway clearance after highly effective CFTR modulators: normalizing life and reducing treatment burden","volume":"58","author":"Goetz","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"19","key":"10.1016\/j.jcf.2025.11.016_bib0009","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2025.11.016_bib0010","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.016_bib0011","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a Clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.016_bib0012","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2022.05.005","article-title":"Research letter: the impact of elexacaftor\/tezacaftor\/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis","volume":"21","author":"Song","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.016_bib0013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2023.05.001","article-title":"Use of cystic fibrosis inhaled medication before and after elexacaftor\/tezacaftor\/ivacaftor initiation","volume":"23","author":"Manika","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.016_bib0014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12931-024-03089-2","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis","volume":"26","author":"Gramegna","year":"2025","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.016_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jcf.2024.11.004","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on utilization of routine therapies in cystic fibrosis: danish nationwide register study","volume":"24","author":"R\u00e5ket","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.016_bib0016","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.016_bib0017","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2021.08.014","article-title":"Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?","volume":"21","author":"Granger","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2025.11.016_bib0018","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1002\/ppul.26126","article-title":"Pulmonary medication adherence among children and adults with cystic fibrosis: is there an association with disease severity?","volume":"57","author":"Hatziagorou","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.016_bib0019","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jcf.2021.07.003","article-title":"Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation","volume":"21","author":"Sawicki","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.016_bib0020","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1569-1993(24)00963-9","article-title":"121 Effect of elexacaftor\/tezacaftor\/ivacaftor on long-term lung function and BMI trajectory","volume":"23","author":"Solomon","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.11.016_bib0021","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ppul.27018","article-title":"Medication utilization and lung function changes after initiation of treatment with elexacaftor\/tezacaftor\/ivacaftor","volume":"59","author":"De Vuyst","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.016_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.jcf.2025.11.016_bib0023","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1513\/AnnalsATS.202404-366OC","article-title":"Impact of discontinuing both hypertonic saline and dornase alfa after elexacaftor-Tezacaftor-ivacaftor in cystic fibrosis","volume":"21","author":"Mayer-Hamblett","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.016_bib0024","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2024.08.008","article-title":"Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial","volume":"24","author":"Gifford","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.016_bib0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.12.009","article-title":"Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes","volume":"12","author":"Sawicki","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.016_bib0026","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2011.03.005","article-title":"Longitudinal association between medication adherence and lung health in people with cystic fibrosis","volume":"10","author":"Eakin","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.016_bib0027","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2019.10.025","article-title":"Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials","volume":"19","author":"Davies","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.016_bib0028","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ppul.22546","article-title":"Managing treatment complexity in cystic fibrosis: challenges and opportunities","volume":"47","author":"Sawicki","year":"2012","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"10.1016\/j.jcf.2025.11.016_bib0029","first-page":"133","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"issue":"20","key":"10.1016\/j.jcf.2025.11.016_bib0030","first-page":"134","article-title":"Elexacaftor\/tezacaftor\/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","author":"Morgan","year":"2024","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.016_bib0031","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis: the importance of reducing Treatment burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:44:35Z","timestamp":1781883875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1569199325025305"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.016","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor\/tezacaftor\/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}